Tempest CEO granted 269,621 stock options

Tempest Therapeutics, Inc. CEO, President and director Matthew Angel, also a 10% owner, reported a grant of employee stock options on February 4, 2026.

Rhea-AI Filing Summary

Tempest Therapeutics, Inc. CEO, President and director Matthew Angel, also a 10% owner, reported a grant of employee stock options on February 4, 2026. He received options to purchase 269,621 shares of common stock at an exercise price of $2.38 per share, expiring on February 3, 2036.

According to the vesting schedule, 25% of the underlying shares will vest on February 4, 2027, with the remaining shares vesting in 36 equal monthly installments thereafter, subject to his continued service. Following this award, he beneficially owns 269,621 derivative securities directly.

Insider Trade Summary

Grant/Award: 269,621 shares

Grant/Award 1 txn

Insider Angel Matthew

Role CEO and President

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Option (right to buy)	269,621	$0.00	$0.00

Holdings After Transaction: Employee Stock Option (right to buy) — 269,621 contracts (Direct)

Footnotes (1)

1. F1. This option shall vest with respect to 25% of the total number of shares underlying the option on February 4, 2027 and the remaining shares shall vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service.

FAQ

What insider transaction did TPST CEO Matthew Angel report on this Form 4?

Matthew Angel reported receiving an employee stock option grant for 269,621 shares of Tempest Therapeutics common stock. The options were awarded on February 4, 2026, giving him the right to buy these shares at a fixed exercise price of $2.38 per share until February 3, 2036.

How many Tempest Therapeutics (TPST) shares are covered by the new stock options?

The new employee stock option grant covers 269,621 shares of Tempest Therapeutics common stock. These options are derivative securities, meaning they represent the right to acquire underlying shares if exercised according to the specified price, vesting schedule, and expiration terms disclosed in the filing.

What is the exercise price and expiration date of the TPST CEO’s stock options?

The employee stock options have an exercise price of $2.38 per share and expire on February 3, 2036. This means Matthew Angel can choose to buy up to 269,621 shares at $2.38 any time after vesting and before the February 2036 expiration date.

How do the Tempest Therapeutics CEO’s options vest over time?

The options vest with 25% of the total shares on February 4, 2027. The remaining 75% then vest in 36 equal monthly installments, provided Matthew Angel continues in service. This creates a multi-year vesting schedule that gradually increases his exercisable option holdings.

What does transaction code "A" mean in the TPST Form 4 filing?

Transaction code "A" indicates an acquisition of derivative securities, typically through a grant or award rather than a market purchase. In this case, Matthew Angel received 269,621 employee stock options as compensation, adding to his beneficially owned derivative securities position in Tempest Therapeutics.

How many Tempest Therapeutics derivative securities does Matthew Angel own after this grant?

After the reported transaction, Matthew Angel beneficially owns 269,621 derivative securities in the form of employee stock options. These are held directly, and each option is linked to one share of Tempest Therapeutics common stock, subject to the vesting and exercise conditions described in the filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/06/2026 - 04:26 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Angel Matthew

(Last) (First) (Middle)

C/O TEMPEST THERAPEUTICS, INC.

2000 SIERRA POINT PARKWAY, SUITE 400

(Street)

BRISBANE CA 94005

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Tempest Therapeutics, Inc. [ TPST ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	CEO and President

3. Date of Earliest Transaction (Month/Day/Year)
02/04/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$2.38	02/04/2026		A		269,621		(1)	02/03/2036	Common Stock	269,621	$0	269,621	D

Explanation of Responses:

1. This option shall vest with respect to 25% of the total number of shares underlying the option on February 4, 2027 and the remaining shares shall vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service.

	/s/ Matthew Angel	02/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.